Presence of serum tripartite motif-containing 21 antibodies in patients with esophageal squamous cell carcinoma

Cancer Science

Volumn 97, Issue 5, 2006, Pages 380-386

  Kuboshima, Mari ^a   Shimada, Hideaki ^a   Liu, Tian Ling ^a   Nomura, Fumio ^a   Takiguchi, Masaki ^a   Hiwasa, Takaki ^a   Ochiai, Takenori ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GENE PRODUCT; PROTEIN TRIM21; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIGEN DETECTION; ARTICLE; BLOOD SAMPLING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS CARCINOMA; FEMALE; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SERODIAGNOSIS; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR LOCALIZATION; TUMOR VOLUME; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; DNA-BINDING PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL NEOPLASMS; FEMALE; GENE LIBRARY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 33645535762     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00192.x     Document Type: Article

References (37)

1. Isono K, Ochiai T. Recent advances of treatment of cancer of the esophagus (review). Ann Cancer Res Ther 1992; 1: 9-16.
2. Shimada H, Nabeya Y, Okazumi S et al. Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery 2003; 133: 486-94.
3. Daly JM, Karnell LH, Menck HR. National Cancer Data Base report on esophageal carcinoma. Cancer 1996; 78: 1820-8.
4. Shimada H, Kitabayashi H, Nabeya Y et al. Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery 2003; 133: 24-31.
5. Kim YH, Ajani JA, Ota DM, Lunch P, Roth JA. Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach. Cancer 1995; 75: 451-6.
6. Munck-Wikland E, Kuylenstierna R, Wahren B, Lindholm J, Haglund S. Tumor markers carcinoembryonic antigen, CA 50, and CA 19-9 and squamous cell carcinoma of the esophagus. Pretreatment screening. Cancer 1988; 62: 2281-6.
7. McKnight A, Mannell A, Shperling I. The role of carbohydrate antigen 19-9 as a tumour marker of oesophageal cancer. Br J Cancer 1989; 60: 249-51.
8. Foley EJ. Attempts to induce immunity against mammary adenocarcinoma in inbred mice. Cancer Res 1953; 13: 578-80.
9. Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 1957; 18: 769-78.
10. Sahin U, Tureci O, Schmitt H et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995; 92: 11810-3.
11. Ludwig Institute for Cancer Research/Academy of Cancer Immunology/ European Cancer Immunome Program [website]. Cancer immunome database. Available from URL: http://www2.licr.org/CancerImmunomeDB/.
12. Chen YT, Scanlan MJ, Sahin U et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997; 94: 1914-8.
13. Shimada H, Takeda A, Arima M et al. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer 2000; 89: 1677-83.
14. Shimada H, Nakajima K, Ochiai T et al. Detection of serum p53 antibodies in patients with esophageal squamous cell carcinoma: Correlation with clinicopathologic features and tumor markers. Oncol Rep 1998; 5: 871-4.
15. Shimada H, Nabeya Y, Okazumi S et al. Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery 2002; 132: 41-7.
16. Nakashima K, Shimada H, Ochiai T et al. Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. Int J Cancer 2004; 112: 1029-35.
17. Shimada H, Nakashima K, Ochiai T et al. Serological identification of tumor antigens of esophageal squamous cell carcinoma. Int J Oncol 2005; 26: 77-86.
18. Takahashi K, Kanazawa H, Chan H, Hosono T, Takahara M, Sato K. A case of esophageal carcinoma metastatic to the mandible and characterization of two cell lines (T.T. and T.Tn.). Jpn J Oral Maxillofac Surg 1990; 36: 307-16.
19. Shimada H, Shimizu T, Ochiai T et al. Preclinical study of adenoviral p53 gene therapy for esophageal cancer. Surg Today 2001; 31: 597-604.
20. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
21. Sobin LH, Wittekind CH, eds. UICC TNM Classification of Malignant Tumors. 6th ed. New York: John Wiley & Sons, 2000.
22. Shimada H, Nabeya Y, Okazumi S et al. Prognostic significance of CYFRA 21-1 in patients with esophageal squamous cell carcinoma. J Am Coll Surg 2003; 196: 573-8.
23. Laemmli U. Cleavage of structural proteins during the assembly of the head of bacteriophage. Nature 1970; 227: 680-5.
24. Reymond A, Meroni G, Fantozzi A et al. The tripartite motif family identifies cell compartments. EMBO J 2001; 20: 2140-51.
25. Frank MB, Itoh K, Fujisaku A, Pontarotti P, Mattei MG, Neas BR. The mapping of the human 52-kD Ro/SSA autoantigen gene to human chromosome 11, and its polymorphisms. Am J Hum Genet 1993; 52: 183-91.
26. Tureci O, Sahin U, Zwick C, Koslowski M, Seitz G, Pfreundschuh M. Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc Natl Acad Sci USA 1998; 95: 5211-6.
27. Xu L, Yang L, Moitra PK et al. BTBD1 and BTBD2 colocalize to cytoplasmic bodies with the RBCC/tripartite motif protein, TRIM5-delta. Exp Cell Res 2003; 288: 84-93.
28. Stremlau M, Owens CW, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5-alpha restricts HIV-1 infection in Old World monkeys. Nature 2004; 427: 848-53.
29. Itoh K, Itoh Y, Frank MB. Protein heterogeneity in the human Ro/SSA ribonucleoproteins: The 52- and 60-kD Ro/SSA autoantigens are encoded by separate genes. J Clin Invest 1991; 87: 177-86.
30. Xue D, Shi H, Smith JD et al. A lupus-like syndrome develops in mice lacking the Ro 60-kDa protein, a major lupus autoantigen. Proc Natl Acad Sci USA 2003; 100: 7503-8.
31. Ben-Chetrit E, Gandy BJ, Tan EM, Sullivan KF. Isolation and characterization of a cDNA clone encoding the 60-kD component of the human SS-A/Ro ribonucleoprotein autoantigen. J Clin Invest 1989; 83: 1284-92.
32. Keech CL, Gordon TP, McCluskey J. Cytoplasmic accumulation of the 52 kDa R0/SS-A nuclear autoantigen in tranfected cell lines. J Autoimmunity 1995; 8: 699-712.
33. Lawley W, Doherty A, Denniss S et al. Rapid lupus autoantigen relocalization and reactive oxygen species accumulation following ultraviolet irradiation of human keratinocytes. Rheumatology 2000; 39: 253-61.
34. Ohlsson M, Jonsson R, Brokstad KA. Subcellular redistribution and surface exposure of the Ro52, Ro60 and La48 autoantigens during apoptosis in human ductal epithelial cells: A possible mechanism in the pathogenesis of Sjogren's syndrome. Scand J Immunol 2002; 56: 456-69.
35. Labazi M, Phillips AC. Oncogenes as regulators of apoptosis. Essays Biochem 2003; 39: 89-104.
36. Jonkers J, Berns A. Oncogene addiction: Sometimes a temporary slavery. Cancer Cell 2004; 6: 535-8.
37. 2+ binding domain of the human Ro 52 kDa protein is a target for conformation-dependent autoantibodies. J Autoimmun 1998; 11: 11-7.